Retatrutide is a triple agonist for GLP-1, GIP, and glucagon receptors, which produces its superior weight loss results compared to single or dual agonists
You finish a full meal rice, dal, sabzi, the works
In fact, this is a good time to pour a bit of cold water on the GLP-1 revolution that Ive probably spent a bit too much time inadvertently hyping up
By Route of Administration, Injectables Remain the Backbone Through 2035 Injectable formulations account for nearly 99% of obesity GLP-1 therapy use in 2025, reflecting their status as the established delivery route for both semaglutide and tirzepatide
For example, data on Wegovy shows that it offers cardiovascular benefits
Injection-site reactions (redness, itching) may occur with injectable formulations